Review





Similar Products

5 fluorouracil  (MedChemExpress)
98
MedChemExpress 5 fluorouracil
5 Fluorouracil, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/5+fluorouracil/5-Fluorouracil/bio_rxiv__64898__2026__10__11__756515-197-6-14
Average 98 stars, based on 1 article reviews
5 fluorouracil - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
5 fu  (TargetMol)
95
TargetMol 5 fu
5 Fu, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/5+fluorouracil/5-Fluorouracil/pm42835308-54-35-37
Average 95 stars, based on 1 article reviews
5 fu - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
fluorouracil  (MedChemExpress)
98
MedChemExpress fluorouracil
Fluorouracil, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/5+fluorouracil/5-Fluorouracil/pm42855855-76-21-27
Average 98 stars, based on 1 article reviews
fluorouracil - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
capecitabine  (TargetMol)
95
TargetMol capecitabine
Time-to-onset patterns of fluoropyrimidine-associated adverse-event reports in FAERS. (A) Empirical cumulative distributions of TTO records according to fluoropyrimidine. (B) Distribution of TTO values across the three principal fluoropyrimidines. (C–F) Empirical cumulative distributions of TTO records according to gastrointestinal System Organ Class categories. (G–J) Observed TTO distributions and fitted Weibull curves for fluorouracil, <t>capecitabine,</t> trifluridine, and all fluoropyrimidines, respectively. (K–N) Numbers and proportions of TTO records within predefined reporting intervals. Drug-specific results were as follows: fluorouracil, n = 5,413, median TTO 22 days (IQR, 7–70 days), α = 50.25 (95% CI 47.89–52.61), and β = 0.602 (95% CI 0.591–0.613); capecitabine, n = 12,092, median TTO 42 days (IQR, 16–110 days), α = 81.94 (95% CI 79.75–84.13), and β = 0.706 (95% CI 0.697–0.714); trifluridine, n = 2,661, median TTO 45 days (IQR, 20–97 days), α = 75.18 (95% CI 71.63–78.72), and β = 0.853 (95% CI 0.830–0.876); and all fluoropyrimidines, n = 20,167, median TTO 37 days (IQR, 13–98 days), α = 71.80 (95% CI 70.26–73.33), and β = 0.684 (95% CI 0.677–0.690). Exact numbers of unique evaluable reports and TTO records, median values, IQRs, ranges, and Weibull estimates are provided in . Priority-stratified findings are provided in . These empirical distributions describe the timing of submitted FAERS reports and should not be interpreted as cumulative incidence. TTO analysis was limited to FAERS because complete onset-date information was unavailable in JADER and CVARD.
Capecitabine, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/5+fluorouracil/5-Fluorouracil/pmc13658617-317-4-5
Average 95 stars, based on 1 article reviews
capecitabine - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
tpa  (MedChemExpress)
98
MedChemExpress tpa
Time-to-onset patterns of fluoropyrimidine-associated adverse-event reports in FAERS. (A) Empirical cumulative distributions of TTO records according to fluoropyrimidine. (B) Distribution of TTO values across the three principal fluoropyrimidines. (C–F) Empirical cumulative distributions of TTO records according to gastrointestinal System Organ Class categories. (G–J) Observed TTO distributions and fitted Weibull curves for fluorouracil, <t>capecitabine,</t> trifluridine, and all fluoropyrimidines, respectively. (K–N) Numbers and proportions of TTO records within predefined reporting intervals. Drug-specific results were as follows: fluorouracil, n = 5,413, median TTO 22 days (IQR, 7–70 days), α = 50.25 (95% CI 47.89–52.61), and β = 0.602 (95% CI 0.591–0.613); capecitabine, n = 12,092, median TTO 42 days (IQR, 16–110 days), α = 81.94 (95% CI 79.75–84.13), and β = 0.706 (95% CI 0.697–0.714); trifluridine, n = 2,661, median TTO 45 days (IQR, 20–97 days), α = 75.18 (95% CI 71.63–78.72), and β = 0.853 (95% CI 0.830–0.876); and all fluoropyrimidines, n = 20,167, median TTO 37 days (IQR, 13–98 days), α = 71.80 (95% CI 70.26–73.33), and β = 0.684 (95% CI 0.677–0.690). Exact numbers of unique evaluable reports and TTO records, median values, IQRs, ranges, and Weibull estimates are provided in . Priority-stratified findings are provided in . These empirical distributions describe the timing of submitted FAERS reports and should not be interpreted as cumulative incidence. TTO analysis was limited to FAERS because complete onset-date information was unavailable in JADER and CVARD.
Tpa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/5+fluorouracil/5-Fluorouracil/10__1038_slash_s41467___026___77546___5-516-8-11
Average 98 stars, based on 1 article reviews
tpa - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
reference anticancer drug 5 fluorouracil  (MedChemExpress)
98
MedChemExpress reference anticancer drug 5 fluorouracil
Time-to-onset patterns of fluoropyrimidine-associated adverse-event reports in FAERS. (A) Empirical cumulative distributions of TTO records according to fluoropyrimidine. (B) Distribution of TTO values across the three principal fluoropyrimidines. (C–F) Empirical cumulative distributions of TTO records according to gastrointestinal System Organ Class categories. (G–J) Observed TTO distributions and fitted Weibull curves for fluorouracil, <t>capecitabine,</t> trifluridine, and all fluoropyrimidines, respectively. (K–N) Numbers and proportions of TTO records within predefined reporting intervals. Drug-specific results were as follows: fluorouracil, n = 5,413, median TTO 22 days (IQR, 7–70 days), α = 50.25 (95% CI 47.89–52.61), and β = 0.602 (95% CI 0.591–0.613); capecitabine, n = 12,092, median TTO 42 days (IQR, 16–110 days), α = 81.94 (95% CI 79.75–84.13), and β = 0.706 (95% CI 0.697–0.714); trifluridine, n = 2,661, median TTO 45 days (IQR, 20–97 days), α = 75.18 (95% CI 71.63–78.72), and β = 0.853 (95% CI 0.830–0.876); and all fluoropyrimidines, n = 20,167, median TTO 37 days (IQR, 13–98 days), α = 71.80 (95% CI 70.26–73.33), and β = 0.684 (95% CI 0.677–0.690). Exact numbers of unique evaluable reports and TTO records, median values, IQRs, ranges, and Weibull estimates are provided in . Priority-stratified findings are provided in . These empirical distributions describe the timing of submitted FAERS reports and should not be interpreted as cumulative incidence. TTO analysis was limited to FAERS because complete onset-date information was unavailable in JADER and CVARD.
Reference Anticancer Drug 5 Fluorouracil, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/5+fluorouracil/5-Fluorouracil/10__1007_slash_s43450___026___00801___9-39-1-9
Average 98 stars, based on 1 article reviews
reference anticancer drug 5 fluorouracil - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
m8407 5 fluorouracil 5 fu sigma aldrich  (MedChemExpress)
98
MedChemExpress m8407 5 fluorouracil 5 fu sigma aldrich
Time-to-onset patterns of fluoropyrimidine-associated adverse-event reports in FAERS. (A) Empirical cumulative distributions of TTO records according to fluoropyrimidine. (B) Distribution of TTO values across the three principal fluoropyrimidines. (C–F) Empirical cumulative distributions of TTO records according to gastrointestinal System Organ Class categories. (G–J) Observed TTO distributions and fitted Weibull curves for fluorouracil, <t>capecitabine,</t> trifluridine, and all fluoropyrimidines, respectively. (K–N) Numbers and proportions of TTO records within predefined reporting intervals. Drug-specific results were as follows: fluorouracil, n = 5,413, median TTO 22 days (IQR, 7–70 days), α = 50.25 (95% CI 47.89–52.61), and β = 0.602 (95% CI 0.591–0.613); capecitabine, n = 12,092, median TTO 42 days (IQR, 16–110 days), α = 81.94 (95% CI 79.75–84.13), and β = 0.706 (95% CI 0.697–0.714); trifluridine, n = 2,661, median TTO 45 days (IQR, 20–97 days), α = 75.18 (95% CI 71.63–78.72), and β = 0.853 (95% CI 0.830–0.876); and all fluoropyrimidines, n = 20,167, median TTO 37 days (IQR, 13–98 days), α = 71.80 (95% CI 70.26–73.33), and β = 0.684 (95% CI 0.677–0.690). Exact numbers of unique evaluable reports and TTO records, median values, IQRs, ranges, and Weibull estimates are provided in . Priority-stratified findings are provided in . These empirical distributions describe the timing of submitted FAERS reports and should not be interpreted as cumulative incidence. TTO analysis was limited to FAERS because complete onset-date information was unavailable in JADER and CVARD.
M8407 5 Fluorouracil 5 Fu Sigma Aldrich, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/5+fluorouracil/5-Fluorouracil/pm42594868-228-55-63
Average 98 stars, based on 1 article reviews
m8407 5 fluorouracil 5 fu sigma aldrich - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
mir146a 5p  (MedChemExpress)
98
MedChemExpress mir146a 5p
Time-to-onset patterns of fluoropyrimidine-associated adverse-event reports in FAERS. (A) Empirical cumulative distributions of TTO records according to fluoropyrimidine. (B) Distribution of TTO values across the three principal fluoropyrimidines. (C–F) Empirical cumulative distributions of TTO records according to gastrointestinal System Organ Class categories. (G–J) Observed TTO distributions and fitted Weibull curves for fluorouracil, <t>capecitabine,</t> trifluridine, and all fluoropyrimidines, respectively. (K–N) Numbers and proportions of TTO records within predefined reporting intervals. Drug-specific results were as follows: fluorouracil, n = 5,413, median TTO 22 days (IQR, 7–70 days), α = 50.25 (95% CI 47.89–52.61), and β = 0.602 (95% CI 0.591–0.613); capecitabine, n = 12,092, median TTO 42 days (IQR, 16–110 days), α = 81.94 (95% CI 79.75–84.13), and β = 0.706 (95% CI 0.697–0.714); trifluridine, n = 2,661, median TTO 45 days (IQR, 20–97 days), α = 75.18 (95% CI 71.63–78.72), and β = 0.853 (95% CI 0.830–0.876); and all fluoropyrimidines, n = 20,167, median TTO 37 days (IQR, 13–98 days), α = 71.80 (95% CI 70.26–73.33), and β = 0.684 (95% CI 0.677–0.690). Exact numbers of unique evaluable reports and TTO records, median values, IQRs, ranges, and Weibull estimates are provided in . Priority-stratified findings are provided in . These empirical distributions describe the timing of submitted FAERS reports and should not be interpreted as cumulative incidence. TTO analysis was limited to FAERS because complete onset-date information was unavailable in JADER and CVARD.
Mir146a 5p, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/5+fluorouracil/5-Fluorouracil/pmc13480036-112-36-49
Average 98 stars, based on 1 article reviews
mir146a 5p - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
fu group  (MedChemExpress)
98
MedChemExpress fu group
Time-to-onset patterns of fluoropyrimidine-associated adverse-event reports in FAERS. (A) Empirical cumulative distributions of TTO records according to fluoropyrimidine. (B) Distribution of TTO values across the three principal fluoropyrimidines. (C–F) Empirical cumulative distributions of TTO records according to gastrointestinal System Organ Class categories. (G–J) Observed TTO distributions and fitted Weibull curves for fluorouracil, <t>capecitabine,</t> trifluridine, and all fluoropyrimidines, respectively. (K–N) Numbers and proportions of TTO records within predefined reporting intervals. Drug-specific results were as follows: fluorouracil, n = 5,413, median TTO 22 days (IQR, 7–70 days), α = 50.25 (95% CI 47.89–52.61), and β = 0.602 (95% CI 0.591–0.613); capecitabine, n = 12,092, median TTO 42 days (IQR, 16–110 days), α = 81.94 (95% CI 79.75–84.13), and β = 0.706 (95% CI 0.697–0.714); trifluridine, n = 2,661, median TTO 45 days (IQR, 20–97 days), α = 75.18 (95% CI 71.63–78.72), and β = 0.853 (95% CI 0.830–0.876); and all fluoropyrimidines, n = 20,167, median TTO 37 days (IQR, 13–98 days), α = 71.80 (95% CI 70.26–73.33), and β = 0.684 (95% CI 0.677–0.690). Exact numbers of unique evaluable reports and TTO records, median values, IQRs, ranges, and Weibull estimates are provided in . Priority-stratified findings are provided in . These empirical distributions describe the timing of submitted FAERS reports and should not be interpreted as cumulative incidence. TTO analysis was limited to FAERS because complete onset-date information was unavailable in JADER and CVARD.
Fu Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/5+fluorouracil/5-Fluorouracil/pm42567984-100-1-17
Average 98 stars, based on 1 article reviews
fu group - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier

Image Search Results


Time-to-onset patterns of fluoropyrimidine-associated adverse-event reports in FAERS. (A) Empirical cumulative distributions of TTO records according to fluoropyrimidine. (B) Distribution of TTO values across the three principal fluoropyrimidines. (C–F) Empirical cumulative distributions of TTO records according to gastrointestinal System Organ Class categories. (G–J) Observed TTO distributions and fitted Weibull curves for fluorouracil, capecitabine, trifluridine, and all fluoropyrimidines, respectively. (K–N) Numbers and proportions of TTO records within predefined reporting intervals. Drug-specific results were as follows: fluorouracil, n = 5,413, median TTO 22 days (IQR, 7–70 days), α = 50.25 (95% CI 47.89–52.61), and β = 0.602 (95% CI 0.591–0.613); capecitabine, n = 12,092, median TTO 42 days (IQR, 16–110 days), α = 81.94 (95% CI 79.75–84.13), and β = 0.706 (95% CI 0.697–0.714); trifluridine, n = 2,661, median TTO 45 days (IQR, 20–97 days), α = 75.18 (95% CI 71.63–78.72), and β = 0.853 (95% CI 0.830–0.876); and all fluoropyrimidines, n = 20,167, median TTO 37 days (IQR, 13–98 days), α = 71.80 (95% CI 70.26–73.33), and β = 0.684 (95% CI 0.677–0.690). Exact numbers of unique evaluable reports and TTO records, median values, IQRs, ranges, and Weibull estimates are provided in . Priority-stratified findings are provided in . These empirical distributions describe the timing of submitted FAERS reports and should not be interpreted as cumulative incidence. TTO analysis was limited to FAERS because complete onset-date information was unavailable in JADER and CVARD.

Journal: Frontiers in Immunology

Article Title: Fluoropyrimidine-associated gastrointestinal toxicity: pharmacovigilance reporting signals and in vitro evidence of epithelial injury, barrier impairment, and inflammatory responses

doi: 10.3389/fimmu.2026.1934652

Figure Lengend Snippet: Time-to-onset patterns of fluoropyrimidine-associated adverse-event reports in FAERS. (A) Empirical cumulative distributions of TTO records according to fluoropyrimidine. (B) Distribution of TTO values across the three principal fluoropyrimidines. (C–F) Empirical cumulative distributions of TTO records according to gastrointestinal System Organ Class categories. (G–J) Observed TTO distributions and fitted Weibull curves for fluorouracil, capecitabine, trifluridine, and all fluoropyrimidines, respectively. (K–N) Numbers and proportions of TTO records within predefined reporting intervals. Drug-specific results were as follows: fluorouracil, n = 5,413, median TTO 22 days (IQR, 7–70 days), α = 50.25 (95% CI 47.89–52.61), and β = 0.602 (95% CI 0.591–0.613); capecitabine, n = 12,092, median TTO 42 days (IQR, 16–110 days), α = 81.94 (95% CI 79.75–84.13), and β = 0.706 (95% CI 0.697–0.714); trifluridine, n = 2,661, median TTO 45 days (IQR, 20–97 days), α = 75.18 (95% CI 71.63–78.72), and β = 0.853 (95% CI 0.830–0.876); and all fluoropyrimidines, n = 20,167, median TTO 37 days (IQR, 13–98 days), α = 71.80 (95% CI 70.26–73.33), and β = 0.684 (95% CI 0.677–0.690). Exact numbers of unique evaluable reports and TTO records, median values, IQRs, ranges, and Weibull estimates are provided in . Priority-stratified findings are provided in . These empirical distributions describe the timing of submitted FAERS reports and should not be interpreted as cumulative incidence. TTO analysis was limited to FAERS because complete onset-date information was unavailable in JADER and CVARD.

Article Snippet: 5-Fluorouracil (5-FU,TargetMol, USA, T0984), capecitabine (TargetMol, USA,T1408), and trifluridine ( T70086 ,Psaitong Biotechnology, Beijing,China.)

Techniques: Analysis